Q-omics provides the consensus-scored KIR3DL1 profile across patient tissues and cancer cell-line models. KIR3DL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KIR3DL1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, KIR3DL1 RNA expression shows 7,301 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where KIR3DL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIR3DL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIR3DL1 survival associations across molecular data types. KIR3DL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIR3DL1 RNA expression–survival associations across cancer types. High KIR3DL1 expression shows favorable associations in SKCM, HNSC, KIRC, MESO, UCS and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KIR3DL1 RNA expression.
This table summarizes KIR3DL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIR3DL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIR3DL1 shows lower tumor expression in LUAD, LUSC and BRCA and higher tumor expression in KIRC, KICH and STAD. The KIRC box plot shows higher KIR3DL1 RNA expression in tumor versus normal tissue (log2 FC = +0.439, t-test p < 0.001).
This table shows molecular features associated with KIR3DL1 in patient tissues and cancer cell lines. In patient samples, KIR3DL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIR3DL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
